Delcath Systems (NASDAQ:DCTH) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a buy rating in a report released on Saturday.

Other analysts also recently issued reports about the company. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. BTIG Research raised their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research report on Friday. Finally, Zacks Research raised shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and a consensus price target of $23.17.

Delcath Systems Trading Down 2.3%

NASDAQ DCTH opened at $15.11 on Friday. The firm’s 50 day simple moving average is $12.35 and its 200 day simple moving average is $10.87. The firm has a market capitalization of $521.60 million, a price-to-earnings ratio of 1,512.51 and a beta of 0.52. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $16.38.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.16. The business had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.47%. On average, equities research analysts forecast that Delcath Systems will post -0.88 earnings per share for the current year.

Institutional Trading of Delcath Systems

A number of hedge funds have recently made changes to their positions in DCTH. Deutsche Bank AG increased its stake in shares of Delcath Systems by 5.4% in the fourth quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock valued at $244,000 after buying an additional 1,248 shares during the period. California State Teachers Retirement System acquired a new stake in Delcath Systems during the 2nd quarter worth approximately $26,000. Intech Investment Management LLC boosted its position in Delcath Systems by 13.1% during the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock worth $178,000 after buying an additional 2,035 shares during the period. AWM Investment Company Inc. boosted its position in Delcath Systems by 3.9% during the 4th quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock worth $606,000 after buying an additional 2,279 shares during the period. Finally, Royal Bank of Canada grew its holdings in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after acquiring an additional 2,364 shares during the last quarter. 61.12% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.